Regeneron Pharmaceuticals rose 22.5% in a year. Merck rose 61.8%.

Same industry

REGN against four drug peers, a year at 100

REGN is up 22.5% in a year. Merck is up 61.8%, Eli Lilly 36.1% and Johnson & Johnson 35.7%. Of these four, only AbbVie (+12.4%) did less. Weekly closes, Oct 3, 2025 = 100, on a log scale, so the same percentage move is the same height on every line.

Share this chart

REGN +22.5%. Merck +61.8%, Eli Lilly +36.1%, Johnson & Johnson +35.7%, AbbVie +12.4%. Weekly closes, Oct 3, 2025 = 100, log scale.

Share this chart

End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in REGN’s SEC industry (Pharmaceutical Preparations) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.

REGN: stories, the record and filings →